Shareholders of Evoke Pharma Inc. have approved the proposed acquisition of Intralot’s U.S. operations by Bally’s Corporation, the companies announced.
The deal, valued at approximately $1.05 billion, was greenlit during an extraordinary general meeting of Evoke’s shareholders. The transaction remains subject to customary regulatory approvals and other closing conditions.
Bally’s, a diversified gaming and entertainment company, plans to integrate Intralot’s U.S. assets into its operations. The acquisition expands Bally’s footprint in the U.S. gaming sector, which has seen increased consolidation in recent years.
Evoke Pharma, a specialty pharmaceutical company, will receive the $1.05 billion in cash as part of the agreement. The company has not disclosed specific plans for the proceeds but noted the transaction aligns with its strategic priorities.
The acquisition scheme was first announced in [month, year] and has since undergone shareholder and regulatory scrutiny. Bally’s has not provided further details on the integration timeline or potential cost synergies.
The approval marks a significant step in the deal’s progression, though final closure remains contingent on additional approvals.
